גאלבוס 50 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

VILDAGLIPTIN 50 MG

Commercializzato da:

NOVARTIS PHARMA SERVICES AG

Codice ATC:

A10BH02

Forma farmaceutica:

TABLETS

Via di somministrazione:

PER OS

Prodotto da:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Gruppo terapeutico:

VILDAGLIPTIN

Indicazioni terapeutiche:

Galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• As monotherapy, if diet and exercise are not sufficient, or• In combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.As triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. Galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

Data dell'autorizzazione:

2008-12-01